We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Seeks Comments on its Draft Guideline on Drug Risks in Pregnancy
EMA Seeks Comments on its Draft Guideline on Drug Risks in Pregnancy
The European Medicines Agency (EMA) is seeking comments from the public on a draft pharmacovigilance guideline published yesterday on assessing the risk of drug-related fetal abnormalities and when to employ a pregnancy prevention program (PPM) or risk minimization measures (RMM).